Metropolis Healthcare Q1 Results Review - Strong Growth In B2C Aiding Better Margins: ICICI Securities

ICICI Securities Report

Metropolis Healthcare Ltd. Q1 FY25 Ebitda margin of 25.2% (up 240 basis points) beat our estimates. An 18.4% YoY spike in its B2C business (54% of sales) drove recovery in its margins; business-to-business (37% of sales) grew a modest 12.4% YoY.

It has added 120 new specialised tests in the last two years, perking up growth to 14% YoY in its business to consumer specialised tests; Metropolis’ omni-channel approach boosted B2C revenue of Truhealth by 28% YoY.

Metropolis Healthcare has extended its presence to 650 in Q1 FY25, from 300 cities in FY23 and aims to add 350 towns to its network in a few years. FY25E Ebitda margins shall be at the higher-end of its 25–26% guidance. It is also scouting an M&A opportunity to lift nearterm earnings growth.

We raise our FY25–26E Ebitda by ~2%. Retain Add; discounted cash flow -based target price raised to Rs 2,279.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.